CD69 and melanoma: However, the CD8+ TIL in ADU-S100 + anti-PD-L1 vs. ADU-S100 only treated B16 melanomas expressed significantly higher levels of early activation marker CD69, consistent with their enhanced functional status, but they exhibited no significant changes in Granzyme B or PD1 expression (Figure 3C, Supplementary Figure 4D).